Ticker: AGIO

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) has reported its financial results for the quarter ended June 30, 2025, reflecting both growth in revenue from its lead product, PYRUKYND®, and significant operating losses primarily driven by research and development expenses. Key Financial Highlights: ...

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) has released its quarterly financial results for Q1 2025, highlighting both challenges and advancements in its development pipeline. Positive Aspects: Revenue Growth: Product revenue increased to $8.7 million for Q1 2025, up from $8.2 million in Q1 2024...